Literature DB >> 25408937

Hemorrhagic Recurrence in Diffuse Astrocytoma without Malignant Transformation.

Hyun Joo Baek1, Seong Min Kim1, Seung Young Chung1, Moon Sun Park1.   

Abstract

Although uncommon, hemorrhage can be a complication of low grade glioma with an unfavorable prognosis such as transformation to higher grade glioma. To our knowledge, hemorrhagic recurrence of World Health Organization Grade II, diffuse astrocytoma without malignant transformation has not been reported. Thus, we report a case of diffuse astrocytoma with hemorrhagic recurrence without malignant transformation. The patient had undergone craniotomy and tumor removal 7 years previously. Annual follow-up MRIs had shown evidence of slow tumor recurrence. With the sudden onset of seizure, the patient was diagnosed as hemorrhagic recurrence and underwent second tumor removal highly suspecting malignant change into higher grade glioma. Histopathology confirmed diffuse astrocytoma without malignant changes. As the patient's postoperative condition was excellent, we plan to withhold chemotherapy and radiation therapy for use as a later treatment option.

Entities:  

Keywords:  Astrocytoma; Glioma; Recurrence

Year:  2014        PMID: 25408937      PMCID: PMC4231623          DOI: 10.14791/btrt.2014.2.2.119

Source DB:  PubMed          Journal:  Brain Tumor Res Treat        ISSN: 2288-2405


  12 in total

Review 1.  Haemorrhagic presentation of low-grade glioma in adults.

Authors:  A Della Puppa; F Zustovich; M Gardiman; R Manara; D Cecchin; R Scienza
Journal:  Acta Neurochir (Wien)       Date:  2007-08-06       Impact factor: 2.216

Review 2.  Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature.

Authors:  Elisabetta Marton; Alberto Feletti; Enrico Orvieto; Pierluigi Longatti
Journal:  J Neurol Sci       Date:  2006-12-26       Impact factor: 3.181

3.  Age-dependent rate of anaplastic transformation in low-grade astrocytoma.

Authors:  S Shafqat; E T Hedley-Whyte; J W Henson
Journal:  Neurology       Date:  1999-03-10       Impact factor: 9.910

Review 4.  Immediate postoperative radiotherapy or "watch and wait" in the management of adult low-grade glioma?

Authors:  Rolf-Dieter Kortmann; Branislav Jeremic; Michael Weller; Johannes Lutterbach; Frank Paulsen; Michael Bamberg
Journal:  Strahlenther Onkol       Date:  2004-07       Impact factor: 3.621

5.  Bleeding cerebral neoplasms with symptomatic hematoma.

Authors:  B Licata; S Turazzi
Journal:  J Neurosurg Sci       Date:  2003-12       Impact factor: 2.279

6.  Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma.

Authors:  Ichiyo Shibahara; Masayuki Kanamori; Toshihiro Kumabe; Hidenori Endo; Yukihiko Sonoda; Yoshikazu Ogawa; Mika Watanabe; Teiji Tominaga
Journal:  Brain Tumor Pathol       Date:  2009-04-30       Impact factor: 3.298

7.  The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas.

Authors:  Kavita K Mishra; Dev R Puri; Brian T Missett; Kathleen R Lamborn; Michael D Prados; Mitchel S Berger; Anuradha Banerjee; Nalin Gupta; William M Wara; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2006-02-22       Impact factor: 12.300

8.  Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.

Authors:  M Brada; L Viviers; C Abson; F Hines; J Britton; S Ashley; S Sardell; D Traish; A Gonsalves; P Wilkins; C Westbury
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

9.  Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation.

Authors:  Jeremy Rees; Hilary Watt; H Rolf Jäger; Chris Benton; Daniel Tozer; Paul Tofts; Adam Waldman
Journal:  Eur J Radiol       Date:  2008-07-15       Impact factor: 3.528

10.  Rate of spontaneous hemorrhage in histologically proven cases of pilocytic astrocytoma.

Authors:  J Bradley White; David G Piepgras; Bernd W Scheithauer; Joseph E Parisi
Journal:  J Neurosurg       Date:  2008-02       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.